WallStreetZenWallStreetZen

NASDAQ: MGX
Metagenomi Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for MGX

Based on 2 analysts offering 12 month price targets for Metagenomi Therapeutics Inc

Min Forecast
$5.00+320.17%
Avg Forecast
$6.00+404.2%
Max Forecast
$7.00+488.24%

Should I buy or sell MGX stock?

Based on 2 analysts offering ratings for Metagenomi Therapeutics Inc.

Strong Buy
Strong Buy
2 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their MGX stock forecasts and price targets.

MGX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-08-11
lockedlocked$00.00+00.00%2026-07-07

1 of 1

Forecast return on equity

Is MGX forecast to generate an efficient return?

Company
-85.42%
Industry
15.41%
Market
167.7%
MGX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is MGX forecast to generate an efficient return on assets?

Company
-55.35%
Industry
23.16%
MGX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

MGX earnings per share forecast

What is MGX's earnings per share in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
-$2.46
Avg 2 year Forecast
-$2.06
Avg 3 year Forecast
-$1.87

MGX revenue forecast

What is MGX's revenue in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
$6.9M-49.28%
Avg 2 year Forecast
$7.6M-44.33%
Avg 3 year Forecast
$4.5M-66.76%
MGX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

MGX revenue growth forecast

How is MGX forecast to perform vs Biotechnology companies and vs the US market?

Company
-26.59%
Industry
31.75%
Market
13.42%
MGX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
MGX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

MGX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
MGX$1.19$6.00+404.20%Strong Buy
FLNA$0.93$5.00+438.21%Strong Buy
TVGN$6.89N/AN/AHold
VERU$2.63$24.50+833.33%Strong Buy
GRCE$2.12$8.00+277.36%Strong Buy
View Top Biotech Stocks

Metagenomi Therapeutics Stock Forecast FAQ

Is Metagenomi Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: MGX) stock is to Strong Buy MGX stock.

Out of 2 analysts, 2 (100%) are recommending MGX as a Strong Buy, 0 (0%) are recommending MGX as a Buy, 0 (0%) are recommending MGX as a Hold, 0 (0%) are recommending MGX as a Sell, and 0 (0%) are recommending MGX as a Strong Sell.

If you're new to stock investing, here's how to buy Metagenomi Therapeutics stock.

What is MGX's earnings growth forecast for 2026-2028?

(NASDAQ: MGX) Metagenomi Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.07%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31%.

Metagenomi Therapeutics's earnings in 2026 is -$93,462,000.On average, 6 Wall Street analysts forecast MGX's earnings for 2026 to be -$92,909,012, with the lowest MGX earnings forecast at -$103,660,376, and the highest MGX earnings forecast at -$85,678,474. On average, 6 Wall Street analysts forecast MGX's earnings for 2027 to be -$77,662,172, with the lowest MGX earnings forecast at -$90,702,829, and the highest MGX earnings forecast at -$61,878,898.

In 2028, MGX is forecast to generate -$70,790,517 in earnings, with the lowest earnings forecast at -$97,219,380 and the highest earnings forecast at -$31,336,109.

What is MGX's revenue growth forecast for 2026-2028?

(NASDAQ: MGX) Metagenomi Therapeutics's forecast annual revenue growth rate of -26.59% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.75%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.42%.

Metagenomi Therapeutics's revenue in 2026 is $13,561,000.On average, 6 Wall Street analysts forecast MGX's revenue for 2026 to be $259,830,928, with the lowest MGX revenue forecast at $37,021,563, and the highest MGX revenue forecast at $525,479,531. On average, 6 Wall Street analysts forecast MGX's revenue for 2027 to be $285,217,143, with the lowest MGX revenue forecast at $0, and the highest MGX revenue forecast at $665,519,259.

In 2028, MGX is forecast to generate $170,299,189 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $332,740,741.

What is MGX's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: MGX) forecast ROA is -55.35%, which is lower than the forecast US Biotechnology industry average of 23.16%.

What is MGX's Price Target?

According to 2 Wall Street analysts that have issued a 1 year MGX price target, the average MGX price target is $6.00, with the highest MGX stock price forecast at $7.00 and the lowest MGX stock price forecast at $5.00.

On average, Wall Street analysts predict that Metagenomi Therapeutics's share price could reach $6.00 by Aug 11, 2027. The average Metagenomi Therapeutics stock price prediction forecasts a potential upside of 404.2% from the current MGX share price of $1.19.

What is MGX's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: MGX) Metagenomi Therapeutics's current Earnings Per Share (EPS) is -$2.49. On average, analysts forecast that MGX's EPS will be -$2.46 for 2026, with the lowest EPS forecast at -$2.74, and the highest EPS forecast at -$2.27. On average, analysts forecast that MGX's EPS will be -$2.06 for 2027, with the lowest EPS forecast at -$2.40, and the highest EPS forecast at -$1.64. In 2028, MGX's EPS is forecast to hit -$1.87 (min: -$2.57, max: -$0.83).

What is MGX's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: MGX) forecast ROE is -85.42%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.